Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
Autolus Therapeutics (Nasdaq: AUTL) announced the publication of three abstracts for the upcoming 2024 European Hematology Association (EHA) Congress, set for June 13-16, 2024. The studies focus on obecabtagene autoleucel (obe-cel) for treating relapsed/refractory B-Cell acute lymphoblastic leukemia. Key presentations include:
- An oral presentation by Dr. Claire Roddie on survival rates and CAR-T cell persistence in the FELIX study.
- A poster by Dr. Jae H. Park discussing the effects of inotuzumab-containing bridging therapy.
- Another poster by Dr. Claire Roddie on the sensitivity of droplet digital PCR and flow cytometry in measuring CAR-T cell kinetics.
- Presentation of data at a major conference like EHA can boost credibility and visibility.
- Studies show potential impact on survival rates and treatment outcomes for relapsed/refractory B-Cell acute lymphoblastic leukemia.
- Involvement of high-profile researchers like Dr. Claire Roddie and Dr. Jae H. Park strengthens research credibility.
- No new financial or commercial developments announced.
- Results are still in the clinical stage, which involves inherent risks and uncertainties.
- Potential delays in bringing the therapy to market if further trials are required.
LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024.
Oral presentation:
- Title: obecabtagene autoleucel in adult relapsed/refractory B Cell acute lymphoblastic leukemia: Survival and potential impact of CAR-T cell persistence and stem cell transplantation in the FELIX study
Session Title: s419 Acute lymphoblastic leukemia - Clinical 1: Immunotherapy: antibodies and CAR-T cells
Session date and time: Friday, June 14 from 14:45 - 16:00 CEST
Session room: N104
Final Abstract Code: S114
Presenting Author: Dr. Claire Roddie
Poster presentations:
- Title: obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-Cell acute lymphoblastic leukemia (R/R B-ALL): The impact of inotuzumab-containing bridging therapy on treatment outcomes
Session Title: Poster session
Session date and time: Friday, June 14 from 18:00 - 19:00 CEST
Final Abstract Code: P418
Presenting Author: Dr. Jae H. Park - Title: Droplet digital PCR and flow cytometry sensitivity for measuring CAR-T cell kinetics in adult patients with relapsed/refractory B Cell acute lymphoblastic leukemia treated with obecabtagene autoleucel
Session Title: Poster session
Session date and time: Friday, June 14 from 18:00 - 19:00 CEST
Final Abstract Code: P1469
Presenting Author: Dr. Claire Roddie
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com
About obe-cel (AUTO1)
Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Obe-cel is designed with a fast target binding off-rate to minimize excessive activation of the programmed T cells. In clinical trials of obe-cel, this “fast off-rate” profile reduced toxicity and T cell exhaustion, resulting in improved persistence and leading to high levels of durable remissions in r/r Adult ALL patients. The results of the FELIX trial, a pivotal trial for adult ALL, have been submitted and accepted by the FDA with a PDUFA target action date of November 16, 2024. A regulatory submission to the EMA was made in the first half of 2024. In collaboration with Autolus’ academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.
About obe-cel FELIX clinical trial
Autolus’ Phase 1b/2 clinical trial of obe-cel enrolled adult patients with relapsed / refractory B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint was overall response rate, and the secondary endpoints included duration of response, MRD negative CR rate and safety. The trial enrolled over 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe. [NCT04404660]
Contact:
Olivia Manser
+44 (0) 7780 471 568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
What is Autolus Therapeutics presenting at the 2024 EHA Congress?
When and where is the 2024 EHA Congress?
What is obecabtagene autoleucel (obe-cel)?
Who are the presenting authors for Autolus Therapeutics at the EHA Congress?
What is the significance of the FELIX study presented by Autolus Therapeutics?
